Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Capsaicin
Drug ID BADD_D00353
Description Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.
Indications and Usage The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.
Marketing Status approved
ATC Code M02AB01; N01BX04
DrugBank ID DB06774
KEGG ID D00250
MeSH ID D002211
PubChem ID 1548943
TTD Drug ID D0U5CE
NDC Product Code 73102-046; 83158-387; 24286-1559; 45865-773; 49671-001; 49671-002; 59779-381; 68016-067; 69420-6025; 70656-742; 71480-831; 72490-018; 72490-023; 72490-026; 72512-929; 79643-002; 66499-0036; 11822-7448; 50268-195; 50488-1075; 50488-2025; 59088-310; 0363-9902; 69420-7025; 0536-2525; 72490-024; 72512-928; 75249-006; 51686-0002; 41167-7514; 49873-608; 51672-5308; 59316-996; 63187-660; 69842-313; 0536-1118; 70583-733; 71178-777; 72490-032; 72490-037; 53943-904; 59088-479; 72490-014; 72490-028; 72490-029; 72490-033; 72490-034; 72512-930; 81877-515; 50268-198; 52099-8005; 61787-443; 62742-4216; 63868-308; 71073-208; 71178-776; 73102-117; 73141-559; 73287-018; 75249-003; 17353-0010; 10742-8127; 11993-001; 35192-040; 59088-433; 59779-770; 65923-123; 72490-010; 72490-022; 72490-035; 72490-039; 72683-003; 72683-006; 73486-100; 49452-1321; 51686-0003; 62991-3129; 11993-000; 35192-023; 41250-842; 46122-753; 46581-700; 50268-197; 55264-110; 70000-0556; 71659-842; 72490-036; 73454-001; 82345-855; 59568-9200; 50488-1025; 61787-556; 70656-741; 72490-025; 72490-027; 72490-030; 73557-180; 82777-001; 51824-094; 55614-410; 0363-0837; 67510-0303; 68071-3430; 0536-1264; 71101-904; 72490-019; 81533-200; 51927-1807; 81961-001; 49035-890; 50488-1060; 69396-103; 70000-0549; 72490-012; 72490-013; 72490-021; 72847-316; 82531-001; 51552-0129; 11822-4210; 42903-008; 50268-196; 52000-040
UNII S07O44R1ZM
Synonyms Capsaicin | Capsaicine | 8-Methyl-N-Vanillyl-6-Nonenamide | 8 Methyl N Vanillyl 6 Nonenamide | Antiphlogistine Rub A-535 Capsaicin | Axsain | Zacin | Capsidol | Zostrix | Capzasin | Gelcen | Katrum | NGX-4010 | NGX 4010 | NGX4010 | Capsicum Farmaya | Capsin
Chemical Information
Molecular Formula C18H27NO3
CAS Registry Number 404-86-4
SMILES CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Peripheral sensory neuropathy17.09.03.005--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Skin irritation23.03.04.009--Not Available
Skin odour abnormal23.03.03.012--
Tachycardia02.03.02.007--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Vomiting07.01.07.003--
Application site vesicles23.03.01.009; 12.07.01.009; 08.02.01.009--Not Available
Application site dryness23.03.03.024; 12.07.01.011; 08.02.01.011--Not Available
Application site inflammation12.07.01.024; 08.02.01.024--Not Available
Application site papules23.03.03.022; 12.07.01.025; 08.02.01.025--Not Available
Application site hyperaesthesia08.02.01.023; 17.02.06.011; 12.07.01.023--Not Available
Application site paraesthesia17.02.06.012; 12.07.01.026; 08.02.01.026--Not Available
Application site urticaria23.04.02.002; 12.07.01.028; 10.01.06.002; 08.02.01.028--Not Available
Application site swelling08.02.01.027; 12.07.01.027--Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Mediastinal disorder22.09.03.001--Not Available
Application site exfoliation23.03.07.007; 12.07.01.022; 08.02.01.022--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene